Compare Stocks: LSTA vs. ADIL vs. AKTX vs. LPCN
Compare normalized stock price performance over 6 months, 1 year or 2 years. Each line starts at 0%, so different stock prices can be compared on the same scale.
LSTAADILAKTXLPCN
Market Snapshot
Current market context for the selected companies.
LSTA
$1.81
Market Cap
$16.31M
Sector
Healthcare
Industry
Biotechnology
Data through
2026-08-26
ADIL
$5.93
Market Cap
$17.43M
Sector
Healthcare
Industry
Biotechnology
Data through
2026-08-26
AKTX
$9.12
Market Cap
$17.72M
Sector
Healthcare
Industry
Biotechnology
Data through
2026-08-26
LPCN
$2.16
Market Cap
$17.73M
Sector
Healthcare
Industry
Biotechnology
Data through
2026-08-26
Performance
Absolute returns and relative performance versus SPY.
| Metric | LSTA | ADIL | AKTX | LPCN |
|---|---|---|---|---|
| 1 Month | +56.0% | +101.2% | +8.2% | +0.9% |
| 1 Month vs SPY | +52.7% | +97.9% | +4.9% | -2.4% |
| 3 Months | -45.2% | +148.3% | -42.7% | -5.3% |
| 3 Months vs SPY | -47.2% | +146.3% | -44.7% | -7.3% |
| 6 Months | -58.8% | +143.2% | -12.6% | -77.2% |
| 6 Months vs SPY | -69.2% | +132.8% | -23.1% | -87.7% |
| 1 Year | -28.5% | -37.5% | -74.2% | -28.5% |
| 1 Year vs SPY | -47.6% | -56.7% | -93.4% | -47.6% |
| 2 Years | -38.6% | -75.8% | -93.6% | -39.7% |
| 2 Years vs SPY | -75.2% | -112.3% | -130.2% | -76.2% |
Growth & Profitability
Operating growth, margins and capital efficiency.
Valuation
Common valuation multiples shown side by side.
Cash Flow & Balance Sheet
Cash generation and leverage context.
Earnings Outlook
Upcoming earnings expectations when available.